Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alnylam Shifts To Product-Focused Strategy As RNAi Platform Takes A Hit

Executive Summary

Alnylam Pharmaceuticals' strategy announcement on Jan. 7 was “a transformation,” CEO John Maraganore said in an interview at the J.P. Morgan Healthcare Conference, emphasizing that he has “never been more excited” about the prospects for his company.
Advertisement

Related Content

Alnylam’s Comeback: RNAi Developer Partners With Sanofi/Genzyme
The Alnylam Turnaround: What Changed Investors’ Minds?
Alnylam Finds Partner For Liver Cancer Program In China’s Ascletis
Financings Of The Fortnight: Big FOPO For Troubled Alnylam, Plus First European IPO Of 2012 For Adocia
Alnylam Announces 33% Staff Cut, Will Focus Internally On Two Lead RNAi Programs
Roche Announces Internal Review Likely To Result In Staff, Program Cuts
Alnylam Takes Platform Monetization to a Whole New and Non-Exclusive Level
Alnylam Takes Platform Monetization to a Whole New and Non-Exclusive Level
Merck Nabs Pole Position in RNAi With $1.1 Billion Sirna Buy
Merck Nabs Pole Position in RNAi With $1.1 Billion Sirna Buy

Topics

Advertisement
UsernamePublicRestriction

Register

PS053023

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel